Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Change in Account Payables (2020 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Change in Account Payables for 6 consecutive years, with -$2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables fell 537.41% to -$2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.4 million, a 216.65% decrease, with the full-year FY2024 number at $271782.0, up 153.88% from a year prior.
  • Change in Account Payables was -$2.0 million for Q3 2025 at Inhibikase Therapeutics, down from $911832.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $911832.0 in Q2 2025 to a low of -$2.0 million in Q3 2025.
  • A 5-year average of -$62780.5 and a median of -$19585.0 in 2023 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 2415.21% in 2024; the steepest drop was 1104.36% in 2024.
  • Inhibikase Therapeutics' Change in Account Payables stood at $535977.0 in 2021, then tumbled by 30.98% to $369950.0 in 2022, then crashed by 123.73% to -$87794.0 in 2023, then plummeted by 1104.36% to -$1.1 million in 2024, then tumbled by 87.58% to -$2.0 million in 2025.
  • Per Business Quant, the three most recent readings for IKT's Change in Account Payables are -$2.0 million (Q3 2025), $911832.0 (Q2 2025), and $680824.0 (Q1 2025).